- Home
- BAFN vs STTK Comparison
BAFN vs STTK Comparison
Compare BAFN & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAFN
- STTK
- Stock Information
- Founded
- BAFN 1999
- STTK 2016
- Country
- BAFN United States
- STTK United States
- Employees
- BAFN N/A
- STTK N/A
- Industry
- BAFN Savings Institutions
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- BAFN Finance
- STTK Health Care
- Exchange
- BAFN Nasdaq
- STTK Nasdaq
- Market Cap
- BAFN 55.4M
- STTK 56.8M
- IPO Year
- BAFN N/A
- STTK 2020
- Fundamental
- Price
- BAFN $15.96
- STTK $1.23
- Analyst Decision
- BAFN
- STTK Hold
- Analyst Count
- BAFN 0
- STTK 3
- Target Price
- BAFN N/A
- STTK $2.00
- AVG Volume (30 Days)
- BAFN 6.3K
- STTK 127.4K
- Earning Date
- BAFN 01-30-2025
- STTK 02-27-2025
- Dividend Yield
- BAFN 2.01%
- STTK N/A
- EPS Growth
- BAFN 134.19
- STTK N/A
- EPS
- BAFN 2.62
- STTK N/A
- Revenue
- BAFN $83,769,000.00
- STTK $6,435,000.00
- Revenue This Year
- BAFN N/A
- STTK $313.04
- Revenue Next Year
- BAFN N/A
- STTK N/A
- P/E Ratio
- BAFN $6.04
- STTK N/A
- Revenue Growth
- BAFN 10.60
- STTK 382.75
- 52 Week Low
- BAFN $10.40
- STTK $0.94
- 52 Week High
- BAFN $17.50
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- BAFN 68.23
- STTK 52.10
- Support Level
- BAFN $14.41
- STTK $1.11
- Resistance Level
- BAFN $15.74
- STTK $1.36
- Average True Range (ATR)
- BAFN 0.85
- STTK 0.11
- MACD
- BAFN 0.13
- STTK 0.01
- Stochastic Oscillator
- BAFN 65.11
- STTK 56.67
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a one bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.